Regulus Therapeutics Inc.

RGLSCIK 0001505512 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed Apr 30, 2025. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone 0.0033

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

Recent 8-K announcements

Per-item disclosure feed. Item 2.02 is the earnings release.

Jun 25, 2025no items parsed May 8, 2025no items parsed Apr 30, 2025no items parsed Mar 27, 2025no items parsed Mar 13, 2025no items parsed

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Regulus Therapeutics Inc.

Name	Roles	Filings
Aker Christopher Ray	Officer	12
Calsada Crispina	Officer	11
Hagan Joseph P	OfficerDirector	11
Collier Kathryn J	Director	9
Klassen Preston	OfficerDirector	9

Showing 1-5 of 14

Per pagePage 1 of 3Next

All filings

108 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Apr 30, 2025	Papadopoulos Stelios Director	AGrant	62,500	$0.00	$0

Filed		Top transaction	Shares	Price	Value